Skip to main content
Find more clinical trials

Leuprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's (LUCINDA)

Start: November 27, 2020
End: February 2026
Enrollment: 180

What Is This Study About?

This phase 2 trial will assess the effects of an existing drug, leuprolide acetate (Eligard), in women with Mild Cognitive Impairment or Alzheimer's disease who take a stable dose of donepezil (Aricept). Participants will be randomly assigned to take either the study drug or a placebo as an injection given once every 12 weeks for 48 weeks (total of four injections). Researchers will measure cognitive function and overall function, as well as plasma and neuroimaging biomarkers of Alzheimer's by MRI.

Do I Qualify To Participate in This Study?

Minimum Age: 65 Years

Maximum Age: 90 Years

Must have:

  • Female
  • Postmenopausal
  • Probable Alzheimer's disease, or Mild Cognitive Impairment due to Alzheimer's disease, at screening visit
  • MoCA score of more than 11 or a blind MoCA score greater than 8
  • Hachinski score <5 supporting clinical judgment that dementia is not of vascular origin
  • Taking a stable dose of donepezil (Aricept) for at least 90 days, and dosage likely to remain stable throughout the trial
  • Fluent in English
  • Living at home or in a facility other than a nursing home with a caregiver who sees the patient at least three times a week for a total of at least 10 hours and can sign the consent form, accompany the patient on clinic visits, and participate in evaluations

Must NOT have:

  • Significant brain disease other than Alzheimer's, such as schizophrenia, epilepsy, Parkinson's disease, or stroke
  • Current substance abuse
  • Significant depression
  • Physical or psychological magnetic resonance imaging (MRI) contraindications or likely unable to tolerate neuroimaging
  • Prohibited medications: memantine (Namenda); other medications known to affect serum sex hormone or gonadotropin concentrations, such as estrogen and/or progesterone for hormone replacement therapy, goserelin, or danazol
  • Significant systemic illness likely to interfere with participation or completion of study or to affect study results, such as cancer within past 5 years (other than nonmelanoma skin cancer), autoimmune disease, recent myocardial infarction, signs/symptoms of organ failure based on history, ECG, screening laboratory and/or physical exams
  • Receiving other investigational drugs within 30 days or 5 half-lives prior to randomization, whichever is longer
  • Ever treated with active or passive immunization as part of a different clinical trial for Alzheimer's

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 
Study Contact
Sarah Khan
Tom Maloney, PhD

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Florida
University of Miami Miller School of Medicine
Palm Beach Gardens, FL 33410
Not yet recruiting
Susan Rawn, RN
New York
Weill Medical College of Cornell University
New York, NY 10021
Recruiting
Sarah Khan
Wisconsin
University of Wisconsin - Madison
Madison, WI 53792
Not yet recruiting
Rebecca Kintner

Who Sponsors This Study?

Lead: Weill Medical College of Cornell University

Collaborator Sponsor

  • National Institute on Aging (NIA)

Source: ClinicalTrials.gov ID: NCT03649724